How to deal with patients who fail intracavitary treatment
|
|
- Kristin Underwood
- 5 years ago
- Views:
Transcription
1 How to deal with patients who fail intracavitary treatment A. Heidenreich Department of Urology
2 Non-surgical therapy of PCA IMRT SEEDS IGRT HDR-BRACHY HIFU CRYO
3 LDR - Brachytherapy Author Follow-up bned Local relapse metastases Stone, Mon 85% 10% 5% Definition Battermann, PSA-Nadir Mon 0.5ng/ml 89% (ESTRO/EORTC) 8% 3% 3 konsekutive PSA Anstiege (ASTRO) Sylvester, Mon 85% 8% 5% Kwok, Mon 85% 10% 4% Grimm, Mon 85% 10% 3%
4 local relapse after permanent BT 85% 78% 63% 84.7% vs 59.2% Stone N et al., 2009 Int J Radiat Oncol Biol Phys
5 HDR - Brachytherapy bned dependent on risk group classification (D Amico) Deger S et al, Eur Urol 2005; 47: 441
6 Definition of Relapse PSA in 3 consecutive measures 2 weeks apart PSA of 2 ng/ml above Nadir after radiation therapy BUT not every PSA-relapse is a clinical relapse
7 PSA Progression after Radiation Locoregional relapse versus systemic relapse
8 Diagnosis of Local Relapse Pre-Radiation Parameters ct - stage < T3b, N0 PSA <10 ng/ml Gleason Score < 3+4 Posttherapeutic Parameters late PSA - relapse (>1-2 years after radiation) slow PSA (PSADT >10-12 months) Grossfeld et al. Urology 2002; 60 (suppl 3A); 57
9 Verification of Local Relapse Histological verification is mandatory for treatment PCA detection and Ki-67 positivity Biopsy only after PSA Bounce!!
10 Heidenreich A et al., J Urol 2007
11 PET/CT & Local Relapse n = 45 with histologically confirmed local relapse n = 45 with preoperative 11 C-PET/CT local detection rate Correlation Biopsy and 11 C-PET/CT 100% Correlation RPE and 11 C-PET/CT 90% Cancer Foci Total Histology PET/CT Heidenreich A et al., AUA/EAU 2007
12 PET/CT & Local Relapse n = 45 with histologically confirmed local relapse n = 45 with preoperative 11C-PET/CT detection of LN-Metastases positive Uptake 14 (31%) LK Metastasis 9 (20%) LK-Metastasis/positive Uptake 4 LK-Metastasis/negative Uptake 5 Heidenreich A et al., AUA/EAU 2007
13 Treatment of Local Relapse no EBM level 1 or 2 trials all recommendations are based on case studies 90% of treatments after radiation are secondary hormonal treatments (SEER data) Grossfeld et al. Urology 2002; 60(suppl 3A): 57
14 Androgendeprivation n = 124 with local relapse after EBRT immediate versus delayed ADT with LHRH cancer-specific survival 70 and 87 months palliative TUR-P 60% percutaneous nephrostomy 30% suprapubic catheter 40% Schellhammer PF et al., 1993
15 Treatment of Local Relapse Salvage - Prostatectomy Salvage Cystoprostatectomy Bladder neck infiltration, compliance, bladder fibrosis Cryotherapy Seeds MRI guided focal therapy
16 Natural History of PSA Relapse PSA, PSADT > 12 months and histologically verified relapse 5-years metastases-free survival of 92% Pinover et al. Cancer 2003; 97: 1127 Routine Biopsy 2 years after Radiatio 16% Progression after 5 years if Bx - 40% Progression after 5 years if Bx + Pollack et al. Int J Radiat Oncol Biol Phys 2002; 54: 677
17 Radical Salvage Prostatectomy DOGMA Dogma 1: Dogma 2: radical prostatectomy after radiation therapy is not possible if radical prostatectomy will be performed after radiation therapy, significant complications will occur
18 Radical Salvage Prostatectomy Indication (n = 98, ) histologically verified prostate cancer negative CT scan and skeletal scintigraphy PSADT > 12 months PSA 15ng/ml bladder capacity 300ml, competent sphincter, no bladder neck invasion Heidenreich A et al., Eur Urol 2009
19 Radical Salvage Prostatectomy Patients N = 75 Age 65 (45 82) years PSA 7.8 (1.2 24) ng/ml Pretreatment ( ) EBRT 25 HDR Brachytherapy 19 LDR Brachytherapy 31 Heidenreich A et al., Eur Urol 2009
20 Radical Salvage Prostatectomy preoperative Biopsy Gleason % Gleason 7 14% Gleason % Clinical stage ct2c 80% ct3a 20% Heidenreich A et al., Eur Urol 2009
21 Radical Salvage Prostatectomy LDR EBRT HDR TOTAL OR-time (min) 115 (95-130) 128 ( ) 145 ( ) 120 (95-165) Blood loss (ml) 300 ( ) 375 ( ) 420 ( ) 360 ( ) Rectal injury 0/31 1/25 1/19 2/75 (2.7%) Perioperative complications catheterization (days) Hospitalisation (days) 1/31 1/25 2/19 5/75 (4%) 7.5 (7-10) 8 (7-15) 8.5 (7-28) 8 (7-28) 8.5 (8-11) 9.5 (8-12) 10 (8-14) 9.2 (8-14) Heidenreich A et al., Eur Urol 2009
22 Pitfalls of RSP EBRT LDR-Brachy HDR-Brachy Spatium Retzii fibrosis opb (opb) EPLND fibrosis opb (opb) Apex (opb) Fibrose derb Fibrose derb Rectum opb Fibrose Fibrose derb Bladder Neck opb opb opb Heidenreich A et al., Eur Urol 2009
23 Pitfalls of RSP EBRT LDR-Brachy HDR-Brachy Spatium Retzii fibrosis opb (opb) EPLND fibrosis opb (opb) Apex (opb) dense fibrosis Fibrose derb Rectum opb dense fibrosis Fibrose derb Bladder neck opb opb opb Heidenreich A et al., Eur Urol 2009
24 Pitfalls of RSP EBRT LDR-Brachy HDR-Brachy Spatium Retzii fibrosis opb (opb) EPLND fibrosis opb (opb) Apex (opb) dense fibrosis fibrosis Rectum opb dense fibrosis dense fibrosis Bladder neck opb opb opb Heidenreich A et al., Eur Urol 2009
25 Pitfalls of RSP EBRT EBRT + temporary BT Permanent BT EPLND Prostatic apex Recto-prostatic plane Seminal vesicles Bladder neck Heidenreich A et al., Eur Urol 2009
26 Radical Salvage Prostatectomy Continence (PAD-Test) RPE RSP 3 Mon 9 Mon Continence EBRT 79% HDR 67% LDR 92% Mean: 7.9 ± 4.5 months Heidenreich A et al., Eur Urol 2009
27 Complications & Outcome Ward et al. Stephenson Gheiler et al. Heidenreich Year of SRP Year of RT No of patients Median time to SRP (months) PSA > 10 ng/ml 29% 41% 48% 18% pt2c 39% 35% 43% 71% complications 27% 13% 17% 9% Transfusion rates 29% 4.5% Rectal injury 3% 2% 3% 2% Urinary continence 56% 68% 50% 81% Heidenreich A et al., Eur Urol 2009
28 Complications & Outcome n pt3a SV+ LN+ SM+ Gleason 8 Rogers 44 20% 49% 5% 70% No data Garzotto 29 28% 34% 7% 31% No data Gheiler 40 42% 28% 15% 13% No data Amling % 28% 18% 36% No data Stephenson % 17% 7% 6% 17% Heidenreich 75 79% 20% 14% 11% 20% Heidenreich A et al., Eur Urol 2009
29 Complications & Outcome complications and outcome depend on patient selection, type of RT and surgical experience EBRT Temporary BT Permanent BT p n pt2a-c 20 (58.8%) 12 (48%) 30 (81.1%) 0.02* pt3a-b 14 (41.2%) 13 (52%) 7 (19.9%) 0.001* pn1 5 (14.7%) 6 (24%) 1 (2.7%) 0.001* SM+ 7 (20.6%) 7 (28%) 2 (5.4%) 0.001* *p for comparison permanent BT versus EBRT/temporary BT Heidenreich A et al., submitted
30 Complications & Outcome complications and outcome depend on patient selection, type of RT and surgical experience Institution A Institution B p Patients # surgeons 1 1 OR-time (min) 121 (90-165), EPLND in ( ), EPLND in blood loss (ml) 360 ( ) 525 ( ) rectal lesion 2 (2.5%) 3 (14.3%) 0.04 SM+ 8 (10.6%) 10/21 (47.6%) continence 81.3% 80.9% ns Heidenreich A et al., submitted
31 Radikale Salvage Prostatektomie Parameter UVA MVA PSA pre Radiation PSA preoperative biopsy Gleason Score (Rad) Biopsie Gleason Score < 7 (RPE) < 50% positive cylinders LDR Brachytherapy Clinical stage PSA DT > 12 months PSA Nadir Heidenreich A et al., Eur Urol 2009
32 Summary Ideal Candidats Life expectancy 10 years Biopsy Gleason Score 7 50% biopsy cylinders with cancer LDR brachytherapy PSA-DT > 12 months
33 Cryotherapie after Radiatio
34 Cryotherapie after Radiatio Results Complications 31-47% with PSA <0.5 ng/ml after 2-3 years Pisters et al. J Urol 1997; 157: 921. Chin et al. J Urol 2001; 165: 1941 Gheiler et al. Urology 1998; 51: 789. incontinence >12 months - 28% Cespedes et al. J Urol 1997; 157:237. Impotence - 90% Rectal pain 8-40% 6/150 patients need large surgery Isawa et al. J Urol 2000; 164: 1978.
35 Definition Cryotherapy after Radiatio - oncological control - Author Follow-up n PSA pos. Biopsie Bales, % 41% Pisters, PSA-Nadir Mon 0.5ng/ml 150 (ESTRO/EORTC) 58% 23% 3 konsekutive PSA Anstiege (ASTRO) Benoit, Mon 87 42% 31% Chin, Mon % 23% Bahn, 2003 (72) Mon 59 41%??%
36 HIFU & Prostate Cancer
37 HIFU & PCA-Relapse Results Follow-up PSA - Nadir 41 weeks 0.0 ng/ml PSA > 0.4 ng/ml 100% positive Biopsy 40% Chaussy C et al., Urol A 2006: 45: 1271
38 HIFU & Prostate Cancer Summary Current data do not allow any recommendation short Follow-up with high recurrence rate Side effects and complications are considerably high EAU Guidelines: HIFU is an experimental therapy Heidenreich A et al., EAU Guidelines 2009
39 Future Strategies Moman MR et al., 2009 Int J Radiat Biol Phys
40 Summary Radical Salvage Prostatectomy is a viable secondary local treatment option with curative intent Low morbidity and complication no significant perioperative complications incontinence 9 33% incontinence depends on type of radiation, age experienced center in postradiation/chemo surgery
PSA is rising: What to do? After curative intended radiotherapy: More local options?
Klinik und Poliklinik für Urologie und Kinderurologie Direktor: Prof. Dr. H. Riedmiller PSA is rising: What to do? After curative intended radiotherapy: More local options? Klinische und molekulare Charakterisierung
More informationS Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet
S Crouzet, O Rouvière, JY Chapelon, F Mege, X martin, A Gelet Why HIFU? Efficacy demonstrated Real time control of the target Early control of the necrosis area is possible with MRI or TRUS using contrast
More informationProstate Cancer Local or distant recurrence?
Prostate Cancer Local or distant recurrence? Diagnostic flowchart Vanessa Vilas Boas Urologist VFX Hospital FEBU PSA - only recurrence PSA recurrence: 27-53% of all patients undergoing treatment with curative
More informationD. Jeffrey Demanes M.D. FACRO, FACR, FASTRO Director UCLA Brachytherapy combined HDR + EBRT 574 HDR monotherapy Total Patients
Salvage Prostate Brachytherapy D. Jeffrey Demanes M.D. FACRO, FACR, FASTRO Director UCLA Brachytherapy 1996-2013 1515 combined HDR + EBRT 574 HDR monotherapy 36 Salvage 2125 Total Patients No Disclosure
More informationBest Papers. F. Fusco
Best Papers UROLOGY F. Fusco Best papers - 2015 RP/RT Oncological outcomes RP/RT IN ct3 Utilization trends RP/RT Complications Evolving role of elnd /Salvage LND This cohort reflects the current clinical
More informationCase Discussions: Prostate Cancer
Case Discussions: Prostate Cancer Andrew J. Stephenson, MD FRCSC FACS Chief, Urologic Oncology Glickman Urological and Kidney Institute Cleveland Clinic Elevated PSA 1 54 yo, healthy male, family Hx of
More informationFocal Therapy is a Fool s Paradise : The whole prostate must be treated!
Focal Therapy is a Fool s Paradise : The whole prostate must be treated! Ofer Yossepowitch, MD Head, Department of Urology Tel Aviv Sourasky Medical Center Preaching against focal therapy in a focal therapy
More informationBIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY
BIOCHEMICAL RECURRENCE POST RADICAL PROSTATECTOMY AZHAN BIN YUSOFF AZHAN BIN YUSOFF 2013 SCENARIO A 66 year old man underwent Robotic Radical Prostatectomy for a T1c Gleason 4+4, PSA 15 ng/ml prostate
More informationWhen radical prostatectomy is not enough: The evolving role of postoperative
When radical prostatectomy is not enough: The evolving role of postoperative radiation therapy Dr Tom Pickles Clinical Associate Professor, UBC. Chair, Provincial Genito-Urinary Tumour Group BC Cancer
More informationProstatectomy as salvage therapy. Cases. Paul Cathcart - Guy s & St Thomas NHS Trust, London
Prostatectomy as salvage therapy Cases Paul Cathcart - Guy s & St Thomas NHS Trust, London Attributes of brachytherapy appeal to young men who place high utility on genitourinary function At risk of
More informationPSA nadir post LDR Brachytherapy and early Salvage Therapy. Dr Duncan McLaren UK & Ireland Users Group Meeting 2016
PSA nadir post LDR Brachytherapy and early Salvage Therapy Dr Duncan McLaren UK & Ireland Users Group Meeting 2016 Differences in PSA relapse rates based on definition used PSA ng/ml Recurrence ASTRO Recurrence
More informationRadiation Therapy for Prostate Cancer. Resident Dept of Urology General Surgery Grand Round November 24, 2008
Radiation Therapy for Prostate Cancer Amy Hou,, MD Resident Dept of Urology General Surgery Grand Round November 24, 2008 External Beam Radiation Advances Improving Therapy Generation of linear accelerators
More informationSalvage HDR Brachytherapy. Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK
Salvage HDR Brachytherapy Amit Bahl Consultant Clinical Oncologist The Bristol Cancer Institute, UK Disclosures Still No financial disclosures! Limited personal experience of HDR Brachy as salvage option
More information2/14/09. Why Discuss this topic? Managing Local Recurrences after Radiation Failure. PROSTATE CANCER Second Treatment
Why Discuss this topic? Mack Roach III, MD Professor and Chair Radiation Oncology UCSF Managing Local Recurrences after Radiation Failure 1. ~15 to 75% of CaP pts recur after definitive RT. 2. Heterogeneous
More informationBrachytherapy for Prostate Cancer
Brachytherapy for Prostate Cancer Who should be thinking about this and why... Juanita Crook Professor Radiation Oncology University of Toronto Princess Margaret Hospital Many options watchful waiting?
More informationProstate cancer: Update from the BCCA
Prostate cancer: Update from the BCCA Tom Pickles Clinical Professor, UBC Topics 1. Incidence & Utilization rates 2. New developments with External Beam RT IGRT, VMAT and other enhancements Optimizing
More informationPaul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia
Paul F. Schellhammer, M.D. Eastern Virginia Medical School Urology of Virginia Norfolk, Virginia Virginia - Chesapeake Bay Landfall: Virginia Beach, April 29 th, 1607 PSA Failure after Radical Prostatectomy
More informationEmbracing Technology & Timing of Salvage Hormones
Embracing Technology & Timing of Salvage Hormones Andrew Loblaw BSc, MD, MSc, FRCPC, CIP Department of Radiation Oncology Sunnybrook Health Sciences Centre University of Toronto Us Too, Brampton October
More informationDepartment of Urology, Cochin hospital Paris Descartes University
Technical advances in the treatment of localized prostate cancer Pr Michaël Peyromaure Department of Urology, Cochin hospital Paris Descartes University Introduction Curative treatments of localized prostate
More informationIrreversible Electroporation for the Treatment of Recurrent Prostate Cancer
Irreversible Electroporation for the Treatment of Recurrent Prostate Cancer after prostatectomy, radiation therapy and HiFU R. Schwartzberg, E. Günther, N. Klein, S. Zapf, R. El-Idrissi, J. Cooper, B.
More informationNewer Aspects of Prostate Cancer Underwriting
Newer Aspects of Prostate Cancer Underwriting Presented By: Jack Swanson, M.D. Keith Hoffman, NFP Moments Made Possible Objectives To review and discuss Conflicting messages about PSA testing Cautions
More informationAccuracy of post-radiotherapy biopsy before salvage radical prostatectomy
Accuracy of post-radiotherapy biopsy before salvage radical prostatectomy Joshua J. Meeks, Marc Walker*, Melanie Bernstein, Matthew Kent and James A. Eastham Urology Service, Department of Surgery and
More informationUnderstanding the risk of recurrence after primary treatment for prostate cancer. Aditya Bagrodia, MD
Understanding the risk of recurrence after primary treatment for prostate cancer Aditya Bagrodia, MD Aditya.bagrodia@utsouthwestern.edu 423-967-5848 Outline and objectives Prostate cancer demographics
More informationPORT after RP. Adjuvant. Salvage
PORT after RP Adjuvant Or Salvage RT after RP 40-50% PSA relapse after RP in HR Definition: PSA should be undetectable within 6 weeks of RP Initial PSA is measured 6-12 weeks after RP AUA defines biochemical
More informationVALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE
Session 3 Advanced prostate cancer VALUE AND ROLE OF PSA AS A TUMOUR MARKER OF RESPONSE/RELAPSE 1 PSA is a serine protease and the physiological role is believed to be liquefying the seminal fluid PSA
More informationSalvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes
ORIGINAL RESEARCH Salvage prostatectomy for post-radiation adenocarcinoma with treatment effect: Pathological and oncological outcomes Michael J. Metcalfe, MD ; Patricia Troncoso, MD 2 ; Charles C. Guo,
More informationImaging of prostate cancer local recurrences : why and how?
Imaging of prostate cancer local recurrences : why and how? Olivier Rouvière Department of Urinary and Vascular Imaging Hospices Civils de Lyon Lyon - France 1. Preliminary Remarks Preliminary Remarks
More informationModern Dose Fractionation and Treatment Techniques for Definitive Prostate RT
Modern Dose Fractionation and Treatment Techniques for Definitive Prostate RT Daniel J Bourgeois, III MD, MPH Board Certified Radiation Oncologist Southeast Louisiana Radiation Oncology Group (SLROG) Disclosures
More informationExternal Beam Radiotherapy for Prostate Cancer
External Beam Radiotherapy for Prostate Cancer Chomporn Sitathanee, Radiation Oncology Unit Ramathibodi Hospital, Mahidol University Roles of RT in prostate cancer Definitive RT; intact prostate Post radical
More informationHigh Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November D. Maruzzi - L. Ruggera
High Intensity Focused Ultrasounds for the treatment of Prostate Cancers Clinical update November 2014 D. Maruzzi - L. Ruggera HIFU development Second prototype 1995-2000 Integrated Imaging 2006-2010 1993
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationPresentation with lymphadenopathy
Presentation with lymphadenopathy Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Rationale for RRP in N+ disease Prevention local problems Better survival in limited
More informationWhen PSA fails. Urology Grand Rounds Alexandra Perks. Rising PSA after Radical Prostatectomy
When PSA fails Urology Grand Rounds Alexandra Perks Rising PSA after Radical Prostatectomy Issues Natural History Local vs Metastatic Treatment options 1 10 000 men / year in Canada 4000 RRP 15-year PSA
More informationRadiation therapy for localized prostate cancer is a main form of therapy
MANAGEMENT OF RADIATION FAILURE IN PROSTATE CANCER Selection of Salvage Cryotherapy Patients Aaron E. Katz, MD, Mohamed A. Ghafar, MD Department of Urology, College of Physicians & Surgeons of Columbia
More informationExternal Beam Radiation Therapy for Low/Intermediate Risk Prostate Cancer
External Beam Therapy for Low/Intermediate Risk Prostate Cancer Jeff Michalski, M.D. The Carlos A. Perez Distinguished Professor of Department of and Siteman Cancer Center Learning Objectives Understand
More informationNavigating the Stream: Prostate Cancer and Early Detection. Ifeanyi Ani, M.D. TPMG Urology Newport News
Navigating the Stream: Prostate Cancer and Early Detection Ifeanyi Ani, M.D. TPMG Urology Newport News Understand epidemiology of prostate cancer Discuss PSA screening and PSA controversy Review tools
More informationGuidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer
Guidelines for the Management of Prostate Cancer West Midlands Expert Advisory Group for Urological Cancer West Midlands Clinical Networks and Clinical Senate Coversheet for Network Expert Advisory Group
More informationThe Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy. Dr. Matt Andrews Supervisor: Dr. David Bowes
The Role of Adjuvant vs Salvage Radiation Therapy after Prostatectomy Dr. Matt Andrews Supervisor: Dr. David Bowes Objectives Discuss the evidence for adjuvant radiotherapy (ART) EORTC, SWOG, ARO Current
More informationSalvage Cryotherapy. Bernard Malavaud MD, PhD, FEBU Institut Universitaire du Cancer Toulouse (France)
Urethra protection Argon decompression -40 /-60 C 17G hollow needles Salvage Cryotherapy Ice all TRUS positioning & monitoring temperature monitoring of the rectal wall ernard Malavaud MD, PhD, FEU Institut
More information20 Prostate Cancer Dan Ash
20 Prostate Cancer Dan Ash 1 Introduction Prostate cancer is a disease of ageing men for which the aetiology remains unknown. The incidence rises up to 30 to 40% in men over 80. The symptoms of localised
More informationThe benefit of a preplanning procedure - view from oncologist. Dorota Kazberuk November, 2014 Otwock
The benefit of a preplanning procedure - view from oncologist Dorota Kazberuk 21-22 November, 2014 Otwock Brachytherapy is supreme tool in prostate cancer management with a wide range of options in every
More informationProstate Case Scenario 1
Prostate Case Scenario 1 H&P 5/12/16: A 57-year-old Hispanic male presents with frequency of micturition, urinary urgency, and hesitancy associated with a weak stream. Over the past several weeks, he has
More informationPET imaging of cancer metabolism is commonly performed with F18
PCRI Insights, August 2012, Vol. 15: No. 3 Carbon-11-Acetate PET/CT Imaging in Prostate Cancer Fabio Almeida, M.D. Medical Director, Arizona Molecular Imaging Center - Phoenix PET imaging of cancer metabolism
More informationOutcomes of salvage radical prostatectomy following more than one failed local therapy
Original Article - Urological Oncology https://doi.org/10.4111/icu.2018.59.3.152 pissn 2466-0493 eissn 2466-054X Outcomes of salvage radical prostatectomy following more than one failed local therapy Arjun
More informationTRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY
TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 1 TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY BRENDAN CAREY, MD TRANSRECTAL ULTRASOUND-GUIDED PROSTATE BRACHYTHERAPY 2 TRANSRECTAL ULTRASOUND-GUIDED
More informationGUIDELINES ON PROSTATE CANCER
10 G. Aus (chairman), C. Abbou, M. Bolla, A. Heidenreich, H-P. Schmid, H. van Poppel, J. Wolff, F. Zattoni Eur Urol 2001;40:97-101 Introduction Cancer of the prostate is now recognized as one of the principal
More informationSalvage Brachytherapy After External-Beam Irradiation for Prostate Cancer
Salvage Brachytherapy After External-Beam Irradiation for Prostate Cancer Review Article [1] February 01, 2004 By David C. Beyer, MD [2] The options available for patients with recurrent prostate cancer
More informationVALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE. ELENA CASTRO Spanish National Cancer Research Centre
VALUE OF PSA AS TUMOUR MARKER OF RELAPSE AND RESPONSE ELENA CASTRO Spanish National Cancer Research Centre Prostate Preceptorship. Lugano 17-18 October 2017 Prostate Specific Antigen (PSA) has a role in:
More informationLocal treatments for local and metastatic disease: only palliation?
Local treatments for local and metastatic disease: only palliation? Dr. Berardino De Bari Istituto del Radio Brescia The clinical problem... Why to discuss about local relapse in local relapse after EBRT??
More informationMen s Health Topics. Jerome Baca, MS, PA-C. Albuquerque Urology Associates January 6 th, 2018
Men s Health Topics Jerome Baca, MS, PA-C Albuquerque Urology Associates January 6 th, 2018 1 ns 2 Prostate Cancer (pca) Most common type of cancer in men 45-75yo > 95% is adenocarcinoma: CA arising from
More informationRole of surgery. Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam
Role of surgery Theo M. de Reijke MD PhD FEBU Department of Urology Academic Medical Center Amsterdam Surgery and alternative treatments Radical prostatectomy Open Laparoscopic Robot-assisted Temperature
More informationHigh Risk Localized Prostate Cancer Treatment Should Start with RT
High Risk Localized Prostate Cancer Treatment Should Start with RT Jason A. Efstathiou, M.D., D.Phil. Assistant Professor of Radiation Oncology Massachusetts General Hospital Harvard Medical School 10
More informationOpen clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD
CLINICAL TRIALS Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS
More informationOpen clinical uro-oncology trials in Canada
Open clinical uro-oncology trials in Canada Eric Winquist, MD, George Rodrigues, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer A PHASE II PROTOCOL FOR PATIENTS WITH STAGE T1
More informationProstate MRI: Who needs it?
Prostate MRI: Who needs it? Fergus Coakley MD, Professor of Radiology and Urology, Vice Chair for Clinical Services, Chief of Abdominal Imaging, UCSF Abdominal Imaging Magnetic Resonance Science Center
More informationTanaka et al. BMC Cancer (2017) 17:573 DOI /s
Tanaka et al. BMC Cancer (2017) 17:573 DOI 10.1186/s12885-017-3565-1 RESEARCH ARTICLE Comparison of PSA value at last follow-up of patients who underwent low-dose rate brachytherapy and intensity-modulated
More informationGUIDELINEs ON PROSTATE CANCER
GUIDELINEs ON PROSTATE CANCER (Text update March 2005: an update is foreseen for publication in 2010. Readers are kindly advised to consult the 2009 full text print of the PCa guidelines for the most recent
More informationPROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER
PROSTATE CANCER, Radiotherapy ADVANCES in RADIOTHERAPY for PROSTATE CANCER Alberto Bossi Radiotherapy and Oncology Gustave Roussy, Villejuif, France PROSTATE CANCER, Radiotherapy IGRT RT + ADT: short vs
More informationLocalized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA
Localized Prostate Cancer Have we finally got it right? Shingai Mutambirwa Professor & Chair-Division Urology DGMAH & SMU Pretoria SOUTH AFRICA ESMO Cape Town 14 Feb 2018 Disclosures Advisory boards/lecturer/consultant-
More information5. Localised prostate cancer
5. Localised prostate cancer From an anatamopathological point of view, localised prostate cancer is the verified presence of prostate adenocarcinoma without extension to the prostate capsule (pt1-pt2),
More informationRadical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease
Radical Prostatectomy: Management of the Primary From Localized to Oligometasta:c Disease Disclosures I do not have anything to disclose Sexual function causes moderate to severe distress 2 years after
More informationCLINICAL TRIALS Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD
Open clinical uro-oncology trials in Canada George Rodrigues, MD, Eric Winquist, MD London Health Sciences Centre, London, Ontario, Canada bladder cancer AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE II
More informationProstate Cancer Dashboard
Process Risk Assessment Risk assessment: family history assessment of family history of prostate cancer Best Observed: 97 %1 ; Ideal Benchmark:100% measure P8 2 Process Appropriateness of Care Pre-treatment
More informationPROSTATE CANCER SURVEILLANCE
PROSTATE CANCER SURVEILLANCE ESMO Preceptorship on Prostate Cancer Singapore, 15-16 November 2017 Rosa Nadal National Cancer Institute, NIH Bethesda, USA DISCLOSURE No conflicts of interest to declare
More informationFinancial and Other Disclosures
Financial and Other Disclosures Off-label use of drugs, devices, or other agents: None Data from IRB-approved human research is not presented I have the following financial interests or relationships to
More informationMy biopsy shows prostate cancer: How bad is it? How to stage prostate cancer
My biopsy shows prostate cancer: How bad is it? How to stage prostate cancer Giuseppe Petralia giuseppe.petralia@ieo.it Division of Radiology, IEO - European Institute of Oncology IRCCS, Milan Department
More informationPSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up
Original article Original articles PSA bouncing after brachytherapy HDR and external beam radiation therapy: a study of 121 patients with minimum 5-years follow-up Roman Makarewicz, MD, PhD, Prof., Andrzej
More informationQ&A. Overview. Collecting Cancer Data: Prostate. Collecting Cancer Data: Prostate 5/5/2011. NAACCR Webinar Series 1
Collecting Cancer Data: Prostate NAACCR 2010-2011 Webinar Series May 5, 2011 Q&A Please submit all questions concerning webinar content through the Q&A panel Overview NAACCR 2010-2011 Webinar Series 1
More information2015 myresearch Science Internship Program: Applied Medicine. Civic Education Office of Government and Community Relations
2015 myresearch Science Internship Program: Applied Medicine Civic Education Office of Government and Community Relations Harguneet Singh Science Internship Program: Applied Medicine Comparisons of Outcomes
More informationOverview of Radiotherapy for Clinically Localized Prostate Cancer
Session 16A Invited lectures: Prostate - H&N. Overview of Radiotherapy for Clinically Localized Prostate Cancer Mack Roach III, MD Department of Radiation Oncology UCSF Helen Diller Family Comprehensive
More informationPatterns of care for prostate cancer An update
Patterns of care for prostate cancer An update Daniel Moon Director of Robotic Surgery Epworth Healthcare Honorary Clinical Senior Lecturer University of Melbourne Consultant Urologist Peter MacCallum
More informationProstate Cancer: 2010 Guidelines Update
Prostate Cancer: 2010 Guidelines Update James L. Mohler, MD Chair, NCCN Prostate Cancer Panel Associate Director for Translational Research, Professor and Chair, Department of Urology, Roswell Park Cancer
More information18-Oct-16. Take home messages. An update for GPs on modern radiation therapy & hormones for prostate cancer. Session plan
An update for GPs on modern radiation therapy & hormones for prostate cancer A/Prof Jeremy Millar Director Radiation Oncology, Alfred Health Clinical lead Prostate Cancer Outcomes Registry, Monash University
More informationDebate: Whole pelvic RT for high risk prostate cancer??
Debate: Whole pelvic RT for high risk prostate cancer?? WPRT well, at least it ll get the job done.or will it? Andrew K. Lee, MD, MPH Associate Professor Department of Radiation Oncology Using T-stage,
More informationProstate Cancer Innovations in Surgical Strategies Update 2007!
Prostate Cancer Innovations in Surgical Strategies Update 2007! Curtis A. Pettaway, M.D. Professor Department of Urology The University of Texas M. D. Anderson Cancer Center Radical Prostatectomy Pathologic
More informationProstate Cancer UK s Best Practice Pathway
Prostate Cancer UK s Best Practice Pathway TREATMENT Updated August 2018 To be updated in vember Active surveillance What is the patient s stage of disease? Low risk localised PSA < 10 ng/ml and Gleason
More informationProstate Cancer Case Study 1. Medical Student Case-Based Learning
Prostate Cancer Case Study 1 Medical Student Case-Based Learning The Case of Mr. Powers Prostatic Nodule The effervescent Mr. Powers is found by his primary care provider to have a prostatic nodule. You
More informationA CASE OF DEFINITIVE THERAPY FOR LOCALISED PROSTATE CANCER? REPORT OF A UROLOGICAL NIGHTMARE
A CASE OF DEFINITIVE THERAPY FOR LOCALISED PROSTATE CANCER? REPORT OF A UROLOGICAL NIGHTMARE Andreas Sommerhuber, Verena Traxlmayr, Wolfgang Loidl Department of Urology, St. Vincent s Hospital of Charity,
More informationAllinaHealthSystems 1
2018 Dimensions in Oncology Genitourinary Cancer Disclosures I have no financial or commercial relationships relevant to this presentation. Matthew O Shaughnessy, MD, PhD Director of Urologic Oncology
More informationProstate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE
Prostate Cancer UK Best Practice Pathway: ACTIVE SURVEILLANCE Low risk localised PSA < 10 ng/ml and Gleason score 6, and clinical stage T1 - T2a Intermediate risk localised PSA 10-20 ng/ml, or Gleason
More informationCauses of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer
Causes of Raised PSA A very large prostate Gland Infection of urine or Prostate Gland Possibility of prostate Cancer Gleason score Gleason score 2-4: well differentiated (seldom reported now): Low risk
More informationMUSCLE - INVASIVE AND METASTATIC BLADDER CANCER
10 MUSCLE - INVASIVE AND METASTATIC BLADDER CANCER Recommendations from the EAU Working Party on Muscle Invasive and Metastatic Bladder Cancer G. Jakse (chairman), F. Algaba, S. Fossa, A. Stenzl, C. Sternberg
More informationRadical Prostatectomy:
Overtreatment and undertreatment Radical Prostatectomy: An Emerging Standard of Care for High Risk Prostate Cancer Matthew R. Cooperberg, MD,MPH UCSF Radiation Oncology Update San Francisco, CA April 2,
More informationProstate Cancer. David Wilkinson MD Gulfshore Urology
Prostate Cancer David Wilkinson MD Gulfshore Urology What is the Prostate? Male Sexual Gland Adds nutrients and fluids for sperm This fluid is added to sperm during ejaculation Urethra (urine channel)
More informationSalvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients
Urological Oncology SALVAGE CRYOTHERAPY FOR RECURRENT PROSTATE CANCER AFTER RADIATION FAILURE ISMAIL et al. Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case
More information3/22/2014. Goals of this Presentation: in 15 min & 5 min Q & A. Radiotherapy for. Localized Prostate Cancer: What is New in 2014?
3/22/ Goals of this Presentation: in 15 min & 5 min Q & A 1. Potency Preservation. a. Dosimetric considerations Radiotherapy for b. Drugs 2. Update on duration of short term ADT Mack III, MD Professor
More informationPost Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series
Post Radical Prostatectomy Radiation in Intermediate and High Risk Group Prostate Cancer Patients - A Historical Series E. Z. Neulander 1, Z. Wajsman 2 1 Department of Urology, Soroka UMC, Ben Gurion University,
More informationFOCAL THERAPY PROSTATE SEED BRACHYTHERAPY
FOCAL THERAPY PROSTATE SEED BRACHYTHERAPY DR. JOSEPH BUCCI MBBS,FRACP,FRANZCR ST. GEORGE CANCER CARE CENTRE PATIENT 47 2005 66 year old Recently remarried - old childhood sweetheart PSA 6.2, ct1c, Gleason
More informationEORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924
EORTC radiation Oncology Group Intergroup collaboration with RTOG EORTC 1331-ROG; RTOG 0924 Title of the Study Medical Condition Androgen deprivation therapy and high dose radiotherapy with or without
More informationTreatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience
Treatment of Prostate Cancer Local Recurrence After Whole-Gland Cryosurgery With Frameless Robotic Stereotactic Body Radiotherapy: Initial Experience Scott Quarrier, 1 Aaron Katz, 2 Jonathan Haas 3 Abstract
More informationCytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer
Cytoreductive Radical Prostatectomy for de Novo Metastatic Prostate Cancer Timothy G. Wilson, MD Professor and Chair of Urology John Wayne Cancer Institute Santa Monica, California Disclosures I am on
More informationComparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer
Original research Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer Khurram M. Siddiqui, MBBS, MSc, FRCS, FEBU; * Michele Billia, MD; * Andrew Williams,
More informationda Vinci Prostatectomy My Greek personal experience
da Vinci Prostatectomy My Greek personal experience Vassilis Poulakis MD, PhD, FEBU Ass. Prof. of Urology Director of Urologic Clinic Doctors Hospital Athens Laparoscopy - golden standard in Urology -
More informationAlberto Briganti, M.D., PhD
Alberto Briganti, M.D., PhD Professore Orinario di Urologia IRCCS San Raffaele Divisione di Oncologia / Unità di Urologia Urological Research Institute (URI) Università Vita-Salute San Raffaele, Milano
More informationWhen to worry, when to test?
Focus on CME at the University of Calgary Prostate Cancer: When to worry, when to test? Bryan J. Donnelly, MSc, MCh, FRCSI, FRCSC Presented at a Canadian College of Family Practitioner s conference (October
More informationOncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy
european urology 55 (2009) 404 411 available at www.sciencedirect.com journal homepage: www.europeanurology.com Prostate Cancer Oncologic Outcome and Patterns of Recurrence after Salvage Radical Prostatectomy
More informationMolecular Imaging in Prostate Cancer. Carlos Artigas Nuclear Medicine Institut Jules Bordet
Molecular Imaging in Prostate Cancer Carlos Artigas Nuclear Medicine Institut Jules Bordet Introduction 3 different stages of the disease Local treatment with curative intent Introduction 3 different stages
More informationAn Update on Radiation Therapy for Prostate Cancer
An Update on Radiation Therapy for Prostate Cancer David C. Beyer, MD, FACR, FACRO, FASTRO Arizona Oncology Services Phoenix, Arizona Objectives Review significant new data Identify leading trends in PCa
More informationAdjuvant and Salvage Radiation for Prostate Cancer. Savita Dandapani, MD, PhD
Adjuvant and Salvage Radiation for Prostate Cancer Savita Dandapani, MD, PhD DISCLOSURES I am a consultant for Reflexion, receive funding from Bayer, and on the Speaker s Bureau with Astra Zeneca. Post-prostatectomy
More information